Clinical Trial Update: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports a terminated phase 1/2 trial evaluating fenretinide with rituximab for B-cell non-Hodgkin lymphomas; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Fenretinide (fenretinide)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-10-06